For research use only. Not for therapeutic Use.
AM555S（Cat No.:M119217）, also known as TAC-101, is a synthetic retinoid that acts as an antagonist of the retinoic acid receptor (RAR). It exhibits antitumor activity by inhibiting cell proliferation, inducing apoptosis, and blocking angiogenesis. TAC-101 has shown promise in preclinical and clinical studies, particularly for treating hepatocellular carcinoma (HCC) and other solid tumors. Its ability to interfere with retinoic acid signaling pathways also makes it a candidate for combination therapy with other anticancer agents. AM555S holds potential as a novel therapeutic option for managing cancer through its retinoid-based mechanisms.
| Catalog Number | M119217 |
| CAS Number | 125973-56-0 |
| Molecular Formula | C20H27NO3Si2 |
| Purity | ≥95% |
| Storage | Desiccate at RT |
| IUPAC Name | 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid |
| InChI | InChI=1S/C20H27NO3Si2/c1-25(2,3)17-11-15(12-18(13-17)26(4,5)6)19(22)21-16-9-7-14(8-10-16)20(23)24/h7-13H,1-6H3,(H,21,22)(H,23,24) |
| InChIKey | VVTNSTLJOVCBDL-UHFFFAOYSA-N |
| SMILES | C[Si](C)(C)C1=CC(=CC(=C1)C(=O)NC2=CC=C(C=C2)C(=O)O)[Si](C)(C)C |
| Reference | </br>1:Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma. Okusaka T, Ueno H, Ikeda M, Takezako Y, Morizane C.Cancer Sci. 2012 Aug;103(8):1524-30. doi: 10.1111/j.1349-7006.2012.02334.x. Epub 2012 Jun 18. PMID: 22587457 Free Article</br>2:Chemopreventive effect of 4-[3,5-Bis(trimethylsilyl) benzamido] benzoic acid (TAC-101) on MNU-induced colon carcinogenesis in a rat model. Nakayama Y, Inoue Y, Minagawa N, Onitsuka K, Nagata J, Shibao K, Hirata K, Sako T, Nagata N, Yamaguchi K.Anticancer Res. 2009 Jun;29(6):2059-65. PMID: 19528465 Free Article</br>3:Contribution of AP-1 interference induced by TAC-101 to tumor growth suppression in a hepatocellular carcinoma model. Eshima K, Fukaya S, Sugimoto A, Mori T, Yokoi H, Yamamoto Y, Sugiura S, Honda S, Masuko N, Murakami K, Yamasaki Y, Kagechika H.Tumour Biol. 2009;30(1):1-7. doi: 10.1159/000189712. Epub 2009 Jan 12. PMID: 19142034 </br>4:A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB.J Cancer Res Clin Oncol. 2008 Dec;134(12):1325-35. doi: 10.1007/s00432-008-0406-2. Epub 2008 May 27. PMID: 18504614 </br>5:A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma. Ezawa S, Suzuki N, Ohie S, Higashiguchi A, Hosoi F, Kitazato K, Susumu N, Aoki D.Gynecol Oncol. 2008 Mar;108(3):627-31. Epub 2007 Nov 28. PMID: 18048092 </br>6:4- [3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induced fas expression and activated caspase-3 and -8 in a DLD-1 colon cancer cell line. Inoue Y, Nakayama Y, Sako T, Minagawa N, Abe Y, Nagato M, Kadowaki K, Katsuki T, Matsumoto K, Tsurudome Y, Shibao K, Hirata K, Nagata N.In Vivo. 2007 Mar-Apr;21(2):381-7. PMID: 17436592 Free Article</br>7:4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) induces apoptosis in colon cancer partially through the induction of Fas expression. Sako T, Nakayama Y, Minagawa N, Inoue Y, Onitsuka K, Katsuki T, Tsurudome Y, Shibao K, Hirata K, Nagata N, Ohie S, Kohno K, Itoh H.In Vivo. 2005 Jan-Feb;19(1):125-32. PMID: 15796164 Free Article</br>8:A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma. Suzuki N, Aoki D, Oie S, Horiuchi M, Hasegawa Y, Ezawa S, Suzuki A, Susumu N, Hosoi F, Kitazato K, Nozawa S.Gynecol Oncol. 2004 Sep;94(3):643-9. PMID: 15350353 </br>9:TAC-101 inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Lee SJ, Ohashi Y, Sakurai H, Saiki I.Cancer Lett. 2003 Aug 20;198(2):169-77. PMID: 12957355 </br>10:Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. Miyagawa N, Homma T, Kagechika H, Shudo K, Nagai H.Pharmacology. 2003 Jan;67(1):21-31. PMID: 12444300 |
